<?xml version='1.0' encoding='utf-8'?>
<document id="29786959"><sentence text="Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects."><entity charOffset="48-61" id="DDI-PubMed.29786959.s1.e0" text="Ertugliflozin" /><entity charOffset="67-78" id="DDI-PubMed.29786959.s1.e1" text="Sitagliptin" /><entity charOffset="80-89" id="DDI-PubMed.29786959.s1.e2" text="Metformin" /><entity charOffset="91-102" id="DDI-PubMed.29786959.s1.e3" text="Glimepiride" /><entity charOffset="107-118" id="DDI-PubMed.29786959.s1.e4" text="Simvastatin" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e0" e2="DDI-PubMed.29786959.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e0" e2="DDI-PubMed.29786959.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e0" e2="DDI-PubMed.29786959.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e0" e2="DDI-PubMed.29786959.s1.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e0" e2="DDI-PubMed.29786959.s1.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e1" e2="DDI-PubMed.29786959.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e1" e2="DDI-PubMed.29786959.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e1" e2="DDI-PubMed.29786959.s1.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e1" e2="DDI-PubMed.29786959.s1.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e2" e2="DDI-PubMed.29786959.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e2" e2="DDI-PubMed.29786959.s1.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e2" e2="DDI-PubMed.29786959.s1.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e3" e2="DDI-PubMed.29786959.s1.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s1.e3" e2="DDI-PubMed.29786959.s1.e4" /></sentence><sentence text="Ertugliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of adults with type 2 diabetes mellitus, is expected to be coadministered with sitagliptin, metformin, glimepiride, and/or simvastatin"><entity charOffset="0-13" id="DDI-PubMed.29786959.s2.e0" text="Ertugliflozin" /><entity charOffset="17-23" id="DDI-PubMed.29786959.s2.e1" text="sodium" /><entity charOffset="155-166" id="DDI-PubMed.29786959.s2.e2" text="sitagliptin" /><entity charOffset="168-177" id="DDI-PubMed.29786959.s2.e3" text="metformin" /><entity charOffset="179-190" id="DDI-PubMed.29786959.s2.e4" text="glimepiride" /><entity charOffset="199-210" id="DDI-PubMed.29786959.s2.e5" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e0" e2="DDI-PubMed.29786959.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e0" e2="DDI-PubMed.29786959.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e0" e2="DDI-PubMed.29786959.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e0" e2="DDI-PubMed.29786959.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e0" e2="DDI-PubMed.29786959.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e0" e2="DDI-PubMed.29786959.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e1" e2="DDI-PubMed.29786959.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e1" e2="DDI-PubMed.29786959.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e1" e2="DDI-PubMed.29786959.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e1" e2="DDI-PubMed.29786959.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e1" e2="DDI-PubMed.29786959.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e2" e2="DDI-PubMed.29786959.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e2" e2="DDI-PubMed.29786959.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e2" e2="DDI-PubMed.29786959.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e2" e2="DDI-PubMed.29786959.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e3" e2="DDI-PubMed.29786959.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e3" e2="DDI-PubMed.29786959.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e3" e2="DDI-PubMed.29786959.s2.e5" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e4" e2="DDI-PubMed.29786959.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s2.e4" e2="DDI-PubMed.29786959.s2.e5" /></sentence><sentence text=" Four separate open-label, randomized, single-dose, crossover studies were conducted in healthy adults to assess the potential pharmacokinetic interactions between ertugliflozin 15 mg and sitagliptin 100 mg (n = 12), metformin 1000 mg (n = 18), glimepiride 1 mg (n = 18), or simvastatin 40 mg (n = 18)"><entity charOffset="188-199" id="DDI-PubMed.29786959.s3.e0" text="sitagliptin" /><entity charOffset="217-226" id="DDI-PubMed.29786959.s3.e1" text="metformin" /><entity charOffset="245-256" id="DDI-PubMed.29786959.s3.e2" text="glimepiride" /><entity charOffset="275-286" id="DDI-PubMed.29786959.s3.e3" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.29786959.s3.e0" e2="DDI-PubMed.29786959.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29786959.s3.e0" e2="DDI-PubMed.29786959.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s3.e0" e2="DDI-PubMed.29786959.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s3.e0" e2="DDI-PubMed.29786959.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s3.e1" e2="DDI-PubMed.29786959.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s3.e1" e2="DDI-PubMed.29786959.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s3.e1" e2="DDI-PubMed.29786959.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s3.e2" e2="DDI-PubMed.29786959.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s3.e2" e2="DDI-PubMed.29786959.s3.e3" /></sentence><sentence text=" Noncompartmental pharmacokinetic parameters derived from plasma concentration-time data were analyzed using mixed-effects models to assess interactions" /><sentence text=" Coadministration of sitagliptin, metformin, glimepiride, or simvastatin with ertugliflozin had no effect on area under the plasma concentration-time profile from time 0 to infinity (AUCinf ) or maximum observed plasma concentration (Cmax ) of ertugliflozin (per standard bioequivalence boundaries, 80% to 125%)"><entity charOffset="21-32" id="DDI-PubMed.29786959.s5.e0" text="sitagliptin" /><entity charOffset="34-43" id="DDI-PubMed.29786959.s5.e1" text="metformin" /><entity charOffset="45-56" id="DDI-PubMed.29786959.s5.e2" text="glimepiride" /><entity charOffset="61-72" id="DDI-PubMed.29786959.s5.e3" text="simvastatin" /><entity charOffset="78-91" id="DDI-PubMed.29786959.s5.e4" text="ertugliflozin" /><entity charOffset="244-257" id="DDI-PubMed.29786959.s5.e5" text="ertugliflozin" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e0" e2="DDI-PubMed.29786959.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e0" e2="DDI-PubMed.29786959.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e0" e2="DDI-PubMed.29786959.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e0" e2="DDI-PubMed.29786959.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e0" e2="DDI-PubMed.29786959.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e0" e2="DDI-PubMed.29786959.s5.e5" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e1" e2="DDI-PubMed.29786959.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e1" e2="DDI-PubMed.29786959.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e1" e2="DDI-PubMed.29786959.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e1" e2="DDI-PubMed.29786959.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e1" e2="DDI-PubMed.29786959.s5.e5" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e2" e2="DDI-PubMed.29786959.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e2" e2="DDI-PubMed.29786959.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e2" e2="DDI-PubMed.29786959.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e2" e2="DDI-PubMed.29786959.s5.e5" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e3" e2="DDI-PubMed.29786959.s5.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e3" e2="DDI-PubMed.29786959.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e3" e2="DDI-PubMed.29786959.s5.e5" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e4" e2="DDI-PubMed.29786959.s5.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s5.e4" e2="DDI-PubMed.29786959.s5.e5" /></sentence><sentence text=" Similarly, ertugliflozin did not have any impact on AUCinf or Cmax of sitagliptin, metformin, or glimepiride"><entity charOffset="12-25" id="DDI-PubMed.29786959.s6.e0" text="ertugliflozin" /><entity charOffset="71-82" id="DDI-PubMed.29786959.s6.e1" text="sitagliptin" /><entity charOffset="84-93" id="DDI-PubMed.29786959.s6.e2" text="metformin" /><entity charOffset="98-109" id="DDI-PubMed.29786959.s6.e3" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.29786959.s6.e0" e2="DDI-PubMed.29786959.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29786959.s6.e0" e2="DDI-PubMed.29786959.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s6.e0" e2="DDI-PubMed.29786959.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s6.e0" e2="DDI-PubMed.29786959.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s6.e1" e2="DDI-PubMed.29786959.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s6.e1" e2="DDI-PubMed.29786959.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s6.e1" e2="DDI-PubMed.29786959.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s6.e2" e2="DDI-PubMed.29786959.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s6.e2" e2="DDI-PubMed.29786959.s6.e3" /></sentence><sentence text=" AUCinf for simvastatin (24%) and simvastatin acid (30%) increased slightly after coadministration with ertugliflozin and was not considered clinically relevant"><entity charOffset="12-23" id="DDI-PubMed.29786959.s7.e0" text="simvastatin" /><entity charOffset="34-50" id="DDI-PubMed.29786959.s7.e1" text="simvastatin acid" /><entity charOffset="104-117" id="DDI-PubMed.29786959.s7.e2" text="ertugliflozin" /><pair ddi="false" e1="DDI-PubMed.29786959.s7.e0" e2="DDI-PubMed.29786959.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29786959.s7.e0" e2="DDI-PubMed.29786959.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s7.e0" e2="DDI-PubMed.29786959.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s7.e1" e2="DDI-PubMed.29786959.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s7.e1" e2="DDI-PubMed.29786959.s7.e2" /></sentence><sentence text=" All treatments were well tolerated" /><sentence text=" The lack of clinically meaningful pharmacokinetic interactions demonstrates that ertugliflozin can be coadministered safely with sitagliptin, metformin, glimepiride, or simvastatin without any need for dose adjustment"><entity charOffset="82-95" id="DDI-PubMed.29786959.s9.e0" text="ertugliflozin" /><entity charOffset="130-141" id="DDI-PubMed.29786959.s9.e1" text="sitagliptin" /><entity charOffset="143-152" id="DDI-PubMed.29786959.s9.e2" text="metformin" /><entity charOffset="154-165" id="DDI-PubMed.29786959.s9.e3" text="glimepiride" /><entity charOffset="170-181" id="DDI-PubMed.29786959.s9.e4" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e0" e2="DDI-PubMed.29786959.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e0" e2="DDI-PubMed.29786959.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e0" e2="DDI-PubMed.29786959.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e0" e2="DDI-PubMed.29786959.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e0" e2="DDI-PubMed.29786959.s9.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e1" e2="DDI-PubMed.29786959.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e1" e2="DDI-PubMed.29786959.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e1" e2="DDI-PubMed.29786959.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e1" e2="DDI-PubMed.29786959.s9.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e2" e2="DDI-PubMed.29786959.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e2" e2="DDI-PubMed.29786959.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e2" e2="DDI-PubMed.29786959.s9.e4" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e3" e2="DDI-PubMed.29786959.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29786959.s9.e3" e2="DDI-PubMed.29786959.s9.e4" /></sentence><sentence text="" /></document>